BR9801015A - Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal. - Google Patents
Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal.Info
- Publication number
- BR9801015A BR9801015A BR9801015-8A BR9801015A BR9801015A BR 9801015 A BR9801015 A BR 9801015A BR 9801015 A BR9801015 A BR 9801015A BR 9801015 A BR9801015 A BR 9801015A
- Authority
- BR
- Brazil
- Prior art keywords
- surface antigen
- cell culture
- influenza
- animal cell
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201007 | 1997-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9801015A true BR9801015A (pt) | 2000-01-11 |
Family
ID=8228174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9801015-8A BR9801015A (pt) | 1997-04-09 | 1998-04-06 | Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal. |
Country Status (32)
Country | Link |
---|---|
US (1) | US5948410A (pt) |
EP (1) | EP0870508B1 (pt) |
JP (1) | JP5258127B2 (pt) |
KR (1) | KR100593235B1 (pt) |
CN (1) | CN1138564C (pt) |
AR (1) | AR011216A1 (pt) |
AT (1) | ATE197406T1 (pt) |
AU (1) | AU728939B2 (pt) |
BR (1) | BR9801015A (pt) |
CA (1) | CA2234208C (pt) |
CZ (1) | CZ297492B6 (pt) |
DE (2) | DE870508T1 (pt) |
DK (1) | DK0870508T3 (pt) |
DZ (1) | DZ2462A1 (pt) |
ES (1) | ES2129386T3 (pt) |
GR (2) | GR990300017T1 (pt) |
HK (1) | HK1010833A1 (pt) |
HR (1) | HRP980187B1 (pt) |
HU (1) | HUP9800802A3 (pt) |
ID (1) | ID20399A (pt) |
IL (1) | IL123961A (pt) |
NO (1) | NO323349B1 (pt) |
NZ (1) | NZ330131A (pt) |
PL (1) | PL187982B1 (pt) |
PT (1) | PT870508E (pt) |
RU (1) | RU2197264C2 (pt) |
SI (1) | SI0870508T1 (pt) |
SK (1) | SK282614B6 (pt) |
TR (1) | TR199800613A1 (pt) |
TW (1) | TW570803B (pt) |
UA (1) | UA42089C2 (pt) |
ZA (1) | ZA982915B (pt) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ517903A (en) * | 1999-09-24 | 2003-10-31 | Smithkline Beecham Biolog S | One dose intranasal influenza virus vaccine with split influenza viral antigens |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
CN100415769C (zh) * | 2002-02-07 | 2008-09-03 | 中国科学院过程工程研究所 | 寡聚或多聚亚基蛋白质分离纯化的方法 |
AU2003229159B2 (en) | 2002-04-30 | 2008-02-21 | Oncolytics Biotech Inc. | Improved viral purification methods |
US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
EP1597400B8 (en) * | 2003-02-25 | 2013-10-09 | MedImmune, LLC | Methods of producing influenza vaccine compositions |
DE602004028736D1 (de) * | 2003-06-20 | 2010-09-30 | Microbix Biosystems Inc | Verbesserungen bei der virusproduktion |
US8506967B2 (en) | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US8992939B2 (en) | 2003-07-11 | 2015-03-31 | Novavax, Inc. | Highly efficient influenza matrix (M1) proteins |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
EP2471551B1 (en) | 2004-09-09 | 2017-02-01 | Novartis AG | Decreasing potential iatrogenic risks associated with influenza vaccines |
US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
US20090004222A1 (en) | 2004-11-03 | 2009-01-01 | O'hagan Derek | Influenza Vaccination |
EP2368975B1 (en) | 2004-12-23 | 2014-09-17 | MedImmune, LLC | Non-tumorigenic MDCK cell line for propagating viruses |
TW200700078A (en) | 2005-03-23 | 2007-01-01 | Glaxosmithkline Biolog Sa | Novel use |
CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
ATE494906T1 (de) * | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
PT1951299E (pt) | 2005-11-04 | 2012-02-28 | Novartis Vaccines & Diagnostic | Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores |
NZ568210A (en) * | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
HUE051122T2 (hu) * | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
EP1976559B3 (en) | 2006-01-27 | 2020-02-19 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
WO2007126810A2 (en) | 2006-03-31 | 2007-11-08 | Warf - Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
PL2043682T3 (pl) | 2006-07-17 | 2014-09-30 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
GB0614460D0 (en) * | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
WO2008032219A2 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
AU2007347716B2 (en) | 2006-09-15 | 2013-06-20 | Medimmune, Llc | MDCK cell lines supporting viral growth to high titers and bioreactor process using the same |
EP2532362A1 (en) | 2006-12-06 | 2012-12-12 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
US8697154B2 (en) * | 2007-03-05 | 2014-04-15 | Om Pharma Sa | Bacterial extract for respiratory disorders and process for its preparation |
CA2680600A1 (en) | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
AR066405A1 (es) | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
PT2185191E (pt) | 2007-06-27 | 2012-11-27 | Novartis Ag | Vacinas contra a gripe com baixo teor de aditivos |
CA2697373C (en) * | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
CA2718430A1 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
WO2010036760A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
WO2010052214A2 (en) | 2008-11-05 | 2010-05-14 | Glaxosmithkline Biologicals S.A. | Novel method |
EA201171032A1 (ru) | 2009-02-10 | 2012-02-28 | Новартис Аг | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
EP2396032B1 (en) | 2009-02-10 | 2016-09-28 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
AU2010250832B2 (en) | 2009-05-21 | 2013-10-03 | Seqirus UK Limited | Reverse genetics using non-endogenous pol I promoters |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
CN102482666B (zh) | 2009-07-06 | 2017-02-08 | 变异生物技术公司 | 制备囊泡的方法和由其产生的制剂 |
CA2769673A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
WO2011030218A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
CN102741399A (zh) | 2009-10-20 | 2012-10-17 | 诺华有限公司 | 用于病毒拯救的改良反向遗传方法 |
EP2493912B1 (en) | 2009-10-26 | 2020-07-29 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
CN103096921A (zh) | 2010-06-01 | 2013-05-08 | 诺华有限公司 | 不用冻干疫苗抗原浓缩 |
JP5976639B2 (ja) | 2010-06-01 | 2016-08-23 | ノバルティス アーゲー | インフルエンザワクチン抗原の濃縮および凍結乾燥 |
US9610248B2 (en) | 2010-07-06 | 2017-04-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
CA2862871C (en) | 2011-01-13 | 2020-09-22 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
EP2663327A4 (en) | 2011-01-13 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
US20140248320A1 (en) | 2011-10-20 | 2014-09-04 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
CN104302323A (zh) | 2012-01-12 | 2015-01-21 | 变异生物技术公司 | 用于治疗病毒感染的组合物和方法 |
CA2894467A1 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies Inc. | Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents |
AU2013205478B9 (en) | 2012-03-02 | 2014-11-20 | Seqirus UK Limited | Influenza virus reassortment |
AU2013270793A1 (en) | 2012-06-04 | 2014-12-11 | Novartis Ag | Improved safety testing |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
EP2925356A2 (en) | 2012-12-03 | 2015-10-07 | Novartis AG | Reassortant influenza a viren |
CA2905612A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
CN105828835A (zh) | 2013-05-10 | 2016-08-03 | 诺华股份有限公司 | 避免流感疫苗中的发作性嗜睡病风险 |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
CA2914604A1 (en) | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
WO2015009743A1 (en) | 2013-07-15 | 2015-01-22 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
RU2535153C1 (ru) * | 2013-09-04 | 2014-12-10 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства России (ФГУП СПбНИИВС ФМБА России) | Способ получения высокоочищенных вирионных концентратов |
CN105745218B (zh) | 2013-11-15 | 2020-11-06 | 诺华股份有限公司 | 去除残留细胞培养杂质 |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
EP2966093A1 (en) | 2014-07-07 | 2016-01-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
RU2614127C2 (ru) * | 2015-06-04 | 2017-03-22 | Общество с ограниченной ответственностью "НТфарма" | Способ получения концентрата рекомбинантных псевдоаденовирусных частиц, экспрессирующих ген гемагглютинина вируса гриппа A/California/07/2009(H1N1) |
BR112017028011A2 (pt) | 2015-06-26 | 2018-08-28 | Seqirus Uk Ltd | vacinas de gripe correspondentes antigenicamente |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
BR112018000296A2 (pt) | 2015-07-07 | 2018-09-04 | Seqirus UK Limited | ensaios de potência de influenza |
CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
EP3601544A4 (en) | 2017-03-30 | 2021-01-27 | Merck Sharp & Dohme Corp. | ADDITION OF NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND CLEARANCE OF NUCLEIC ACIDS FROM HOST CELLS |
RU2670001C1 (ru) * | 2017-12-25 | 2018-10-17 | Федеральное государственное бюджетное учреждение науки Институт биохимии и физиологии растений и микроорганизмов Российской академии наук | Способ получения белков клеточной поверхности |
AU2019207600A1 (en) | 2018-01-09 | 2020-07-09 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
WO2019183209A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
WO2019183208A1 (en) | 2018-03-20 | 2019-09-26 | Synthetic Biologics, Inc. | Intestinal alkaline phosphatase formulations |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US20230000971A1 (en) | 2019-11-18 | 2023-01-05 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH589453A5 (pt) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
US4317811A (en) * | 1980-09-11 | 1982-03-02 | Merck & Co., Inc. | Herpes simplex type 1 subunit vaccine |
DE3237313A1 (de) * | 1982-10-08 | 1984-04-12 | Werner Heese | Verfahren zur gewinnung und reinigung antigenhaltiger loesungen, insbesondere fuer influenza-viren, aus antigenhaltiger allantoisfluessigkeit |
US4783411A (en) * | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US5006472A (en) * | 1988-06-03 | 1991-04-09 | Miles Inc. | Enzymatic purification process |
RU2080876C1 (ru) * | 1989-02-07 | 1997-06-10 | Био-Текнолоджи Дженерал Корп. | Способ получения очищенных частиц поверхностного антигена гепатита в, очищенная частица поверхностного антигена гепатита в человека и вакцина против гепатита в |
ATE132160T1 (de) * | 1989-03-29 | 1996-01-15 | Univ New York State Res Found | Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza |
DZ1706A1 (fr) * | 1992-08-07 | 2002-02-17 | Merck & Co Inc | Vaccin contre le virus de l'hepatite a. |
HRP950097A2 (en) * | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
WO1996015231A2 (en) * | 1994-11-10 | 1996-05-23 | Immuno Aktiengesellschaft | Method for producing biologicals in protein-free culture |
US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
WO1997004803A1 (fr) * | 1995-08-01 | 1997-02-13 | Pasteur Merieux Serums & Vaccins | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
WO1997011605A1 (en) * | 1995-09-28 | 1997-04-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
-
1998
- 1998-04-01 TW TW087104913A patent/TW570803B/zh not_active IP Right Cessation
- 1998-04-02 DK DK98201056T patent/DK0870508T3/da active
- 1998-04-02 ES ES98201056T patent/ES2129386T3/es not_active Expired - Lifetime
- 1998-04-02 PT PT98201056T patent/PT870508E/pt unknown
- 1998-04-02 SI SI9830010T patent/SI0870508T1/xx unknown
- 1998-04-02 DE DE0870508T patent/DE870508T1/de active Pending
- 1998-04-02 AT AT98201056T patent/ATE197406T1/de active
- 1998-04-02 EP EP98201056A patent/EP0870508B1/en not_active Revoked
- 1998-04-02 TR TR1998/00613A patent/TR199800613A1/xx unknown
- 1998-04-02 DE DE69800383T patent/DE69800383T2/de not_active Expired - Lifetime
- 1998-04-06 CA CA002234208A patent/CA2234208C/en not_active Expired - Lifetime
- 1998-04-06 DZ DZ980072A patent/DZ2462A1/xx active
- 1998-04-06 BR BR9801015-8A patent/BR9801015A/pt not_active Application Discontinuation
- 1998-04-06 HU HU9800802A patent/HUP9800802A3/hu not_active Application Discontinuation
- 1998-04-06 HR HR980187A patent/HRP980187B1/xx not_active IP Right Cessation
- 1998-04-06 NO NO981557A patent/NO323349B1/no not_active IP Right Cessation
- 1998-04-06 ID IDP980519A patent/ID20399A/id unknown
- 1998-04-06 KR KR1019980012018A patent/KR100593235B1/ko not_active IP Right Cessation
- 1998-04-06 IL IL12396198A patent/IL123961A/xx not_active IP Right Cessation
- 1998-04-06 CZ CZ0105098A patent/CZ297492B6/cs unknown
- 1998-04-06 AU AU60659/98A patent/AU728939B2/en not_active Expired
- 1998-04-06 US US09/055,321 patent/US5948410A/en not_active Expired - Lifetime
- 1998-04-06 SK SK445-98A patent/SK282614B6/sk not_active IP Right Cessation
- 1998-04-06 NZ NZ330131A patent/NZ330131A/en not_active IP Right Cessation
- 1998-04-06 CN CNB981080863A patent/CN1138564C/zh not_active Expired - Lifetime
- 1998-04-06 PL PL98325722A patent/PL187982B1/pl unknown
- 1998-04-06 RU RU98106860/13A patent/RU2197264C2/ru active
- 1998-04-06 ZA ZA982915A patent/ZA982915B/xx unknown
- 1998-04-07 JP JP11010198A patent/JP5258127B2/ja not_active Expired - Lifetime
- 1998-04-08 UA UA98041787A patent/UA42089C2/uk unknown
- 1998-04-08 AR ARP980101611A patent/AR011216A1/es not_active Application Discontinuation
- 1998-11-17 HK HK98112068A patent/HK1010833A1/xx not_active IP Right Cessation
-
1999
- 1999-01-01 GR GR990300017T patent/GR990300017T1/el unknown
-
2000
- 2000-11-09 GR GR20000402476T patent/GR3034798T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9801015A (pt) | Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal. | |
Cavanagh et al. | Coronavirus IBV: removal of spike glycopolypeptide S1 by urea abolishes infectivity and haemagglutination but not attachment to cells | |
EP1951296B1 (en) | Cell-derived viral vaccines with low levels of residual cell dna | |
BR9712592A (pt) | Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico | |
Suzuki et al. | New ganglioside analogs that inhibit influenze virus sialidase | |
BR9406007A (pt) | Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano | |
HUP9903822A2 (hu) | Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen | |
PT93393A (pt) | Processo para a preparacao de vacinas e de agentes de diagnostico que contem regioes imunogenicas de proteina e7do virus do papiloma humano do tipo 16 ou anticorpos suscitados contra estas regioes | |
BR0111830A (pt) | Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante | |
US4188375A (en) | Process for the preparation of vaccines | |
Kilbourne et al. | Influenza Virus Polypeptides and Antigens: Summary of Influeza Workshop I | |
BRPI0208301A8 (pt) | vacinas de ácido nucléico para prevenção de infecção por flavivírus | |
BR0210804A (pt) | Vacinação de dose única com mycoplásma hyopneumoniae | |
EP0180288A2 (en) | Vaccine for cytomegalovirus | |
Mikhailov et al. | Baculovirus replication factor LEF-1 is a DNA primase | |
BR0111366A (pt) | Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv) | |
BR9814204A (pt) | "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral" | |
Qiao et al. | Vaccines developed for H5 highly pathogenic avian influenza in China | |
BR9803960A (pt) | Gene de desidrogenase de d-sorbitol. | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
BR0111819A (pt) | Moléculas de ácido nucléico isoladas, e, seq ência de aminoácido isolada | |
Marois et al. | Response of ferrets and monkeys to intranasal infection with human, equine and avian influenza viruses | |
Trudel et al. | Vaccination of rabbits with a bovine herpesvirus type 1 subunit vaccine: adjuvant effect of ISCOMs | |
BR0211178A (pt) | Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico | |
Nakamura et al. | Carbohydrate components of influenza C virions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96). |
|
B25A | Requested transfer of rights approved |
Owner name: SOLVAY BIOLOGICALS B.V. (NL) Free format text: TRANSFERIDO DE: DUPHAR INTERNATIONAL RESEARCH B.V. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: A PETICAO DE NO 20120103292, APRESENTADA EM 01/11/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA DEVIDO AO INDEFERIMENTO DO PEDIDO PUBLICADO NA RPI NO 2184, DE 13/11/2012. |
|
B25E | Requested change of name of applicant rejected |
Owner name: SOLVAY BIOLOGICALS B.V. (NL) |